A newly approved pancreatic cancer drug is offering new hope for some patients, but its nearly half-million-dollar price tag is raising questions about who will be able to access it and how families might afford it.
The treatment’s cost is expected to intensify concerns about affordability as patients and providers weigh potential benefits against financial barriers.
The high price could also shape how quickly the drug becomes available through insurance coverage and other assistance options.
Dr. Marc Kahn joined ARC Las Vegas to discuss what the treatment could mean for pancreatic cancer patients, including the broader implications for access to care. Watch the interview below!
Interview with Dr. Marc Kahn